Adaptimmune Therapeutics (ADAPY)
OTHER OTC:ADAPY
Top Page
Adaptimmune Therapeutics
(OTC:ADAPY)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.03
▲(6.67% Upside)
Action:UpgradedDate:12/25/25
The score is primarily weighed down by weak financial performance, including steep revenue decline, ongoing losses, negative cash flows, and negative equity. Technicals also remain bearish with price below all key moving averages, though oversold indicators suggest potential near-term stabilization. Valuation provides limited support due to negative earnings and no dividend yield data.
Positive Factors
Gross Margin Strength
A 98% TTM gross margin suggests the SPEAR T‑cell platform can capture significant value per unit of revenue and offers high structural operating leverage. If clinical programs and partnerships scale, high gross margins support durable profitability expansion once fixed R&D costs are amortized.
Negative Factors
Steep Revenue Decline
A ~64% TTM revenue drop indicates material setbacks or lumpy partner payments that weaken revenue predictability. Persistent top‑line decline undermines ability to scale fixed investments, erodes bargaining leverage in partnerships, and constrains the timeline for converting high gross margins into sustainable operating profits.
Read all positive and negative factors
Positive Factors
Negative Factors
Gross Margin Strength
A 98% TTM gross margin suggests the SPEAR T‑cell platform can capture significant value per unit of revenue and offers high structural operating leverage. If clinical programs and partnerships scale, high gross margins support durable profitability expansion once fixed R&D costs are amortized.
Read all positive factors
Adaptimmune Therapeutics (ADAPY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.30M
Dividend YieldN/A
Average Volume (3M)50.65M
Price to Earnings (P/E)―
Beta (1Y)-2.74
Revenue Growth-53.61%
EPS Growth-93.14%
CountryUS
Employees506
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding265,051,600
10 Day Avg. Volume4,539,686
30 Day Avg. Volume50,649,310
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)11.47
Price to Sales (P/S)0.76
P/FCF Ratio-1.79
Enterprise Value/Market Cap5.27
Enterprise Value/Revenue0.43
Enterprise Value/Gross Profit0.45
Enterprise Value/Ebitda-0.19
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.5
Revenue Forecast (FY)$20.70M
Adaptimmune Therapeutics Business Overview & Revenue Model
Company Description
Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a gene...
How the Company Makes Money
Adaptimmune Therapeutics generates revenue primarily through collaborations and partnerships with pharmaceutical companies, which may include upfront payments, milestone payments, and royalties on future sales of therapies developed in partnership...
Adaptimmune Therapeutics Financial Statement Overview
Summary
Income Statement
30
Negative
Balance Sheet
20
Very Negative
Cash Flow
25
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 65.08M | 178.03M | 60.28M | 27.15M | 6.15M | 3.96M |
| Gross Profit | 61.70M | 177.96M | 50.42M | -100.58M | -104.94M | -87.61M |
| EBITDA | -149.75M | -52.66M | -128.20M | -155.59M | -155.68M | -125.81M |
| Net Income | -169.76M | -70.81M | -113.87M | -165.46M | -158.09M | -130.09M |
Balance Sheet | ||||||
| Total Assets | 130.63M | 245.96M | 282.62M | 328.92M | 469.55M | 451.14M |
| Cash, Cash Equivalents and Short-Term Investments | 26.06M | 151.60M | 146.94M | 204.60M | 369.58M | 368.22M |
| Total Debt | 48.68M | 74.21M | 25.23M | 23.08M | 25.47M | 23.71M |
| Total Liabilities | 201.59M | 234.11M | 243.10M | 247.04M | 263.58M | 109.92M |
| Stockholders Equity | -70.96M | 11.85M | 39.51M | 81.88M | 205.96M | 341.23M |
Cash Flow | ||||||
| Free Cash Flow | -191.71M | -75.93M | -145.76M | -171.51M | 1.95M | -56.50M |
| Operating Cash Flow | -190.03M | -73.21M | -140.88M | -141.77M | 10.73M | -53.59M |
| Investing Cash Flow | 1.79M | -58.95M | 176.54M | 89.14M | 75.80M | -278.92M |
| Financing Cash Flow | 1.34M | 78.75M | 880.00K | 12.87M | 3.29M | 340.05M |
Adaptimmune Therapeutics Technical Analysis
Negative
0.03
Price Trends
0.02
Negative
0.03
Negative
0.09
Negative
Market Momentum
>-0.01
Negative
49.33
Neutral
81.46
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ADAPY, the sentiment is Negative. The current price of 0.03 is above the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.02, and below the 200-day MA of 0.09, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 49.33 is Neutral, neither overbought nor oversold. The STOCH value of 81.46 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ADAPY.
Adaptimmune Therapeutics Risk Analysis
Adaptimmune Therapeutics disclosed 82 risk factors in its most recent earnings report. Adaptimmune Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Adaptimmune Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $50.25M | -21.38 | -311.80% | ― | 588.40% | 61.76% | |
44 Neutral | $5.30M | -0.52 | -1341.37% | ― | -53.61% | -93.14% | |
44 Neutral | $7.36M | ― | 285.12% | ― | -100.00% | 32.37% | |
43 Neutral | $26.54M | -3.81 | -197.68% | ― | ― | 78.60% |
* Healthcare Sector Average
ADAPY
Adaptimmune Therapeutics
0.02
-0.21
-91.42%
BCAB
BioAtla
4.44
-10.77
-70.82%
SNTI
Senti Biosciences
0.85
-2.28
-72.78%
XLO
Xilio Therapeutics
8.69
-0.83
-8.72%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.